Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 170

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 170
---
 |
| (3) | Mr. Jacobson resigned                                                                                                                 
 from the Company’s board of directors effective as of June 30, 2025.                                                                  |

| (4) | Mr. Flom resigned from                                             
 the Company’s board of directors effective as of December 1, 2024. |

Under the current Company’s policies, each director is to receive
cash compensation of $10,000 biannually, $1,000 per meeting or $300 for a virtual meeting.

<div align='center'>102</div>

Stock Plan

In March 2021, we adopted the Global Share Incentive
Plan (2021) (the “2021 Plan”), providing for the grant of non-qualified stock options and incentive stock options to purchase
shares of our common stock, restricted and unrestricted share awards and grant of restricted stock units, to the employees, services providers,
directors, officers, consultants and affiliates of the Company and its subsidiaries. The Plan, including the Appendix for Israeli taxpayers
was approved by our stockholders by written consent on March 10, 2021. We initially reserved 5,000,000 shares of our Common Stock issuable
under the 2021 Plan.

On November 11, 2024, following discussions with
the management of the Company, the Board has determined that it is advisable and in the best interests of the Company and its stockholders
to further amend the Plan, as amended (“Amendment #2”), to reduce the maximum number of shares reserved for issuance under
the Plan from 20,000,000 shares of Common Stock to 10,000,000 shares of Common Stock. Amendment No. 2 became effective on the date of
the approval by the Board of Directors, but it is subject to approval by the Company’s shareholders within 12 months, pursuant to
section 422(b)(1) of the Internal Revenue Code.

Outstanding Equity Awards at Fiscal Year End

The following table sets
forth certain information as of December 31, 2024 about our 2021 Plan under which our equity securities are authorized for issuance.

| Plan Category                                                  |     | (a)                             
 Number of Securities            
 to be                           
 Issued Upon                     
 Exercise of Outstanding Options |           |     | (b)                          
 Weighted-                    
 Average                      
 Exercise                     
 Price of Outstanding Options |      |     | (c)                                                          
 Number of Securities Remaining Available for Future Issuance 
 Under Equity Compensation Plans (Excluding